CN1221277C - 一种预防和治疗肺炎、支气管炎、咽炎及上呼吸道感染的药物及其制备方法 - Google Patents
一种预防和治疗肺炎、支气管炎、咽炎及上呼吸道感染的药物及其制备方法 Download PDFInfo
- Publication number
- CN1221277C CN1221277C CN 03139769 CN03139769A CN1221277C CN 1221277 C CN1221277 C CN 1221277C CN 03139769 CN03139769 CN 03139769 CN 03139769 A CN03139769 A CN 03139769A CN 1221277 C CN1221277 C CN 1221277C
- Authority
- CN
- China
- Prior art keywords
- radix
- bronchitis
- medicine
- pharyngitis
- respiratory tract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 35
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 25
- 206010006451 bronchitis Diseases 0.000 title claims abstract description 20
- 206010057190 Respiratory tract infections Diseases 0.000 title claims abstract description 19
- 206010046306 Upper respiratory tract infection Diseases 0.000 title claims abstract description 19
- 201000007100 Pharyngitis Diseases 0.000 title claims abstract description 16
- 229940079593 drug Drugs 0.000 title description 13
- 238000000034 method Methods 0.000 title description 4
- 238000011321 prophylaxis Methods 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000007788 liquid Substances 0.000 claims abstract description 11
- 241000207929 Scutellaria Species 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 241000628997 Flos Species 0.000 claims description 13
- 239000010231 banlangen Substances 0.000 claims description 10
- 239000000796 flavoring agent Substances 0.000 claims description 9
- 235000019634 flavors Nutrition 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 238000004821 distillation Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 239000000341 volatile oil Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 241000605447 Anemarrhena Species 0.000 claims description 6
- 241000555712 Forsythia Species 0.000 claims description 6
- 241000202807 Glycyrrhiza Species 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 241000411851 herbal medicine Species 0.000 abstract description 4
- 239000003826 tablet Substances 0.000 abstract description 4
- 239000002775 capsule Substances 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 241000605445 Anemarrhena asphodeloides Species 0.000 abstract 1
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 240000005528 Arctium lappa Species 0.000 abstract 1
- 235000003130 Arctium lappa Nutrition 0.000 abstract 1
- 241000758794 Asarum Species 0.000 abstract 1
- 241000935235 Fritillaria meleagris Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 235000013717 Houttuynia Nutrition 0.000 abstract 1
- 240000000691 Houttuynia cordata Species 0.000 abstract 1
- 241000334160 Isatis Species 0.000 abstract 1
- 235000006751 Platycodon Nutrition 0.000 abstract 1
- 244000274050 Platycodon grandiflorum Species 0.000 abstract 1
- 206010035742 Pneumonitis Diseases 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 229930189914 platycodon Natural products 0.000 abstract 1
- 238000003809 water extraction Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 19
- 210000004072 lung Anatomy 0.000 description 19
- 206010011224 Cough Diseases 0.000 description 14
- 241000700605 Viruses Species 0.000 description 13
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical group N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 210000002381 plasma Anatomy 0.000 description 11
- 229940100050 virazole Drugs 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 206010035737 Pneumonia viral Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 241000712461 unidentified influenza virus Species 0.000 description 7
- 208000009421 viral pneumonia Diseases 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 241000725643 Respiratory syncytial virus Species 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000001088 anti-asthma Effects 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 230000001166 anti-perspirative effect Effects 0.000 description 2
- 239000003213 antiperspirant Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001092500 Photinia x fraseri Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960001660 histamine phosphate Drugs 0.000 description 1
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000005182 tip of the tongue Anatomy 0.000 description 1
- 210000003454 tympanic membrane Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
组别 | n | A值(570nm) | ||
IL-1 | IL-2 | TNF-α | ||
正常组 | 12 | 0.933±0.056 | 0.668±0.031 | 0.040±0.015 |
感染组 | 12 | 0.866±0.051△ | 0.655±0.041 | 0.068±0.017△ |
病毒唑组 | 12 | 0.884±0.047 | 0.652±0.045 | 0.052±0.024* |
JFY小剂量组 | 12 | 0.906±0.048 | 0.688±0.061* | 0.046±0.018* |
JFY大剂量组 | 12 | 0.918±0.039 | 0.713±0.036**△ | 0.042±0.010** |
组别 | n | A值(750nm) |
正常组 | 12 | 0.298±0.028 |
感染组 | 12 | 0.164±0.029△ |
病毒唑组 | 12 | 0.357±0.069** |
JFY小剂量组 | 12 | 0.342±0.596** |
JFY大剂量组 | 12 | 0.322±0.030** |
实验菌种 | 试管号 | |||||||
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | |
金黄色葡萄球菌 | - | - | - | + | + | + | + | - |
乙型溶血性链球菌 | - | - | - | - | + | + | + | - |
肺炎双球菌 | - | - | - | - | + | + | + | - |
流感杆菌 | - | - | + | + | + | + | + | - |
甲型溶血性链球菌 | - | - | - | - | + | + | + | - |
绿浓杆菌 | - | - | - | - | + | + | + | - |
大肠杆菌 | - | - | - | + | + | + | + | - |
白色葡萄球菌 | - | - | - | + | + | + | + | - |
变形杆菌 | - | - | + | + | + | + | + | - |
分组 | 剂量 | 每孔CPE程度 | 平均CPE | CPE抑制率(%) |
解毒利肺口服液 | 5 | 0000 | 0.00 | 100.00 |
2.5 | 1111 | 1.00 | 90.00 | |
1.25 | 4111 | 1.75 | 68.75 | |
0.63 | 1233 | 2.25 | 42.86 | |
0.31 | 1234 | 2.50 | 21.05 | |
0.16 | 3434 | 3.50 | 4.35 | |
0.08 | 4444 | 4.00 | 0.00 | |
病毒唑 | 12.50 | 1111 | 1.00 | 87.88 |
6.25 | 2333 | 2.75 | 53.13 | |
3.13 | 3333 | 3.00 | 30.77 | |
1.56 | 2444 | 3.50 | 16.33 | |
0.78 | 3344 | 3.50 | 9.84 | |
0.39 | 2444 | 3.50 | 5.48 |
0.20 | 3344 | 3.50 | 2.78 | |
0.10 | 4444 | 4.00 | 0.00 | |
正常对照 | 0000 | 0.00 | 100.00 | |
病毒对照 | 4444 | 4.00 | 0.00 |
组别 | n | 咳嗽潜伏期(s) | 咳嗽次数(3min) |
模型对照组 | 12 | 50.90±9.46 | 49.20±14.45 |
急支糖浆组 | 12 | 72.00±20.38* | 25.80±6.68* |
JFY小剂量组 | 12 | 90.50±24.45** | 18.10±10.74** |
JFY大剂量组 | 12 | 100.50±15.92** | 16.70±5.66** |
组别 | n | 气管酚红排泌量(OD值) |
模型对照组 | 12 | 0.061±0.026 |
急支糖浆组 | 12 | 0.101±0.056* |
小剂量组 | 12 | 0.147±0.062**△ |
大剂量组 | 12 | 0.152±0.031**△ |
组别 | n | 排掞量(mL/h) | |
给药前 | 给药后 | ||
正常对照组 | 12 | 44.2±10.0 | 47.4±9.5 |
急支糖浆 | 12 | 48.1±13.0 | 83.4±32.5* |
JFY小剂量组 | 12 | 47.9±10.6 | 91.2±41.2** |
JFY大剂量组 | 12 | 46.2±15.3 | 97.9±19.8** |
组别 | n | 致喘潜伏期(S) |
模型对照组 | 8 | 55.12±29.24 |
急支糖浆 | 8 | 78.75±14.98* |
JFY小剂量组 | 8 | 92.12±13.28**△ |
JFY大剂量组 | 8 | 104.00±14.76**△ |
组别 | n | 肿胀度(mg) | 抑制率(%) |
对照组 | 12 | 18.7±6.07 | |
急支糖浆 | 12 | 13.1±4.01 | 29.9* |
JFY小剂量组 | 12 | 10.8±3.79 | 42.2** |
JFY大剂量组 | 12 | 9.8±3.85 | 47.6** |
组别 | 动物数(n) | 死亡数 | 死亡率(%) |
正常对照 | 18 | 0 | 0.00 |
病毒对照 | 18 | 17 | 94.45 |
病毒唑 | 18 | 0 | 0.00*** |
急支糖浆 | 18 | 14 | 77.78* |
JFY小剂量 | 18 | 9 | 50.00**△ |
JFY大剂量 | 18 | 8 | 44.44**△ |
组别 | 动物数(n) | 肺脂数值(x±s) | 抑制率(%) |
正常对照 | 18 | 0.468±0.132 | - |
病毒对照 | 18 | 1.213±0.308 | - |
病毒唑 | 18 | 1.104±0.326 | 8.99 |
急支糖浆 | 18 | 0.896±0.204 | 26.13* |
JFY小剂量 | 18 | 0.758±0.286 | 37.51** |
JFY大剂量 | 18 | 0.726±0.326 | 40.15**△ |
组别 | 动物数(n) | 血凝滴度 | |
(x±s) | log(x±s) | ||
正常对照 | 18 | - | - |
病毒对照 | 18 | 21.10±1.84 | 1.3036±0.2739 |
病毒唑 | 18 | 2.28±1.67 | 0.321±0.004*** |
急支糖浆 | 18 | 11.78±2.05 | 1.1104±0.3726* |
JFY小剂量 | 18 | 8.43±1.71 | 1.0977±0.2817** |
JFY大剂量 | 18 | 6.15±1.73 | 0.8122±0.3108** |
分组 | 痊愈(例数) | 显效(例数) | 有效(例数) | 无效(例数) | X2值 | P值 |
病毒性肺炎组 | 22(66%) | 8(24%) | 2(0.6%) | 1(0.03%) | 7.944 | 0.047 |
对照组(双黄连) | 10(35.7%) | 8(28.6%) | 6(21.4%) | 4(14.3%) |
分组 | 痊愈(例数) | 显效(例数) | 有效(例数) | 无效(例数) | X2值 | P值 |
急性支气管炎组 | 38(67.9%) | 12(21.4%) | 4(7.1%) | 2(3.6%) | 9.599 | 0.022 |
对照组(双黄连) | 20(41.7%) | 12(25.0%) | 10(20.8%) | 6(12.5%) |
分组 | 痊愈(例数) | 显效(例数) | 有效(例数) | 无效(例数) | X2值 | P值 |
上呼吸道感染组 | 66(75.0%) | 13(14.8%) | 7(8%) | 2(2.3%) | 8.845 | 0.031 |
对照组(急支糖浆) | 23(52.3%) | 10(22.7%) | 6(13.6%) | 5(11.4%) |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03139769 CN1221277C (zh) | 2003-07-09 | 2003-07-09 | 一种预防和治疗肺炎、支气管炎、咽炎及上呼吸道感染的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03139769 CN1221277C (zh) | 2003-07-09 | 2003-07-09 | 一种预防和治疗肺炎、支气管炎、咽炎及上呼吸道感染的药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1480191A CN1480191A (zh) | 2004-03-10 |
CN1221277C true CN1221277C (zh) | 2005-10-05 |
Family
ID=34155089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03139769 Expired - Fee Related CN1221277C (zh) | 2003-07-09 | 2003-07-09 | 一种预防和治疗肺炎、支气管炎、咽炎及上呼吸道感染的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1221277C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101342331B (zh) * | 2008-09-08 | 2011-05-11 | 李娜 | 治疗肺炎和上呼吸道感染的中药喷剂 |
CN101385828B (zh) * | 2008-09-18 | 2011-06-08 | 李爱英 | 一种治疗急慢性上呼吸道炎症的中药 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1296088C (zh) * | 2004-04-30 | 2007-01-24 | 北京中医药大学药厂 | 一种治疗儿童急性咽炎的药物及其制备方法 |
CN100411644C (zh) * | 2006-04-26 | 2008-08-20 | 吉林大学 | 一种治疗慢性咽炎的药物 |
CN101385825B (zh) * | 2008-10-27 | 2011-02-16 | 陈志忠 | 一种防治感冒的中药制剂 |
CN101554446B (zh) * | 2009-05-20 | 2011-01-12 | 贺业生 | 一种治疗慢性咽炎的中药组合物 |
CN102488778A (zh) * | 2011-12-21 | 2012-06-13 | 无锡正大畜禽有限公司 | 一种治疗畜禽上呼吸道感染的中药制剂及其制备方法 |
CN103463282B (zh) * | 2013-10-09 | 2014-12-03 | 河南中医学院 | 一种治疗肉鸡传染性支气管炎的中药 |
CN107714909A (zh) * | 2017-10-30 | 2018-02-23 | 谭宗学 | 一种治疗慢性气管炎、支气管炎、哮喘、肺气肿的中药组合物及其制备方法 |
CN108785559B (zh) * | 2018-09-17 | 2021-07-02 | 河南科技大学第一附属医院 | 一种治疗呼吸道感染的药物及其制备方法 |
CN111249374A (zh) * | 2020-03-16 | 2020-06-09 | 重庆呈品医药有限公司 | 一种治疗新型冠状病毒肺炎病情的抑制和康复口服液 |
CN111956722A (zh) * | 2020-09-10 | 2020-11-20 | 江苏医药职业学院 | 一种抗病毒中药组合物 |
-
2003
- 2003-07-09 CN CN 03139769 patent/CN1221277C/zh not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101342331B (zh) * | 2008-09-08 | 2011-05-11 | 李娜 | 治疗肺炎和上呼吸道感染的中药喷剂 |
CN101385828B (zh) * | 2008-09-18 | 2011-06-08 | 李爱英 | 一种治疗急慢性上呼吸道炎症的中药 |
Also Published As
Publication number | Publication date |
---|---|
CN1480191A (zh) | 2004-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100344313C (zh) | 治疗小儿感冒及反复感冒的中成药及其制备方法 | |
CN1221277C (zh) | 一种预防和治疗肺炎、支气管炎、咽炎及上呼吸道感染的药物及其制备方法 | |
CN1210047C (zh) | 治疗感冒的药物及其制备方法 | |
CN1883560A (zh) | 一种含金莲花的中药复方制剂及其制备方法 | |
CN111249390A (zh) | 一种翘芪复方制剂及其制备方法和用途 | |
CN1883651A (zh) | 一种治疗风热感冒的中药组合物及其制备方法 | |
CN1682842A (zh) | 一种消炎解毒的中药组合物及其制备方法和用途 | |
CN103211901B (zh) | 一种清肺消炎药物及其制备方法 | |
CN1927351A (zh) | 一种清热解毒退烧药物 | |
CN105688157A (zh) | 用于抗猪流感病毒的中药复方制剂及其制备方法 | |
CN105168848A (zh) | 一种清咽的金银花青果桔梗等中药复方口含片 | |
CN116139237B (zh) | 一种防治新型冠状病毒等所致呼吸道感染的中药组合物及其应用 | |
CN111514231A (zh) | 一种麻杏宣肺中药组合物作为流感病毒治疗药物的应用 | |
CN1957994A (zh) | 一种具有清热解毒功能的兽用复方药剂及其制法 | |
CN105535406A (zh) | 一种防治畜禽呼吸道疾病的中药组合物 | |
CN1220495C (zh) | 一种治疗上呼吸道感染的中药及其制备方法 | |
CN1872192A (zh) | 一种药物组合物及其制备方法 | |
CN1289124C (zh) | 一种治疗小儿感冒的药物及其制备方法 | |
CN1229129C (zh) | 止咳贴膏 | |
CN112089799A (zh) | 一种治疗鸡支气管栓塞的复方制剂及其制备方法 | |
CN111514230A (zh) | 一种麻杏宣肺中药胶囊及其制备方法 | |
CN105343503B (zh) | 一种治疗咽喉炎的药物组合物及其应用 | |
CN100344319C (zh) | 治疗泌尿生殖系统疾病的中药组合物及其制备方法和用途 | |
CN106334076B (zh) | 一种用于防治鸡传染性喉气管炎的复方中草药制剂及其应用 | |
CN1291730C (zh) | 一枝黄花在制备治疗和预防sars病毒的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU UNIVERSITY OF TRADITIONAL CHINESE MEDIC Free format text: FORMER OWNER: SHI SHIDE Effective date: 20081031 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20081031 Address after: No. 232 East Ring Road, Panyu District University, Guangzhou, Guangdong Patentee after: Guangzhou University of Chinese Medicine Address before: Guangzhou City, Guangdong province Liuhua Road No. 111, Genenral Hospital of PLA Guangzhou Military Area, Department of Medical Laboratory Patentee before: Shi Shide |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051005 Termination date: 20100709 |